Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

This study has been completed.
Information provided by:
Kamada, Ltd. Identifier:
First received: July 11, 2007
Last updated: December 30, 2009
Last verified: December 2009

July 11, 2007
December 30, 2009
September 2007
Not Provided
Safety and airway inflammation
Same as current
Complete list of historical versions of study NCT00499837 on Archive Site
Sputum microbiology, pulmonary function and serum CRP
Same as current
Not Provided
Not Provided
Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients
Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

Cystic Fibrosis (CF) is an inherited disorder in which mucus-secreting glands in the lungs produce considerable quantity of thick, sticky secretions that clog the airways, promote bacterial growth and lead to chronic obstruction, inflammation and destruction of the airways.

The purpose of this study is to collect data about the resolution of the chronic inflammatory state in addition to assure the safety of the therapy in CF patients.

In CF patients the unregulated inflammatory response overwhelms the normal protease (elastase)/antiprotease (AAT) balance, leading to the accumulation of elastase in the lung, destruction of the lung architecture, severe pulmonary dysfunction, and ultimately death.

Administration of AAT is to address the elastase/antiprotease imbalance in order to prevent destruction of the lung tissue and reduce the inflammatory dysregulation that causes pulmonary dysfunction.

Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Cystic Fibrosis
Drug: Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2008
Not Provided

Inclusion Criteria:

  • Diagnosis of CF by clinical symptoms and positive sweat test or disease inducing mutation.
  • Age >5 yrs
  • Proven ability to perform reproducible PFTs
  • FEV1 >25% predicted
  • Steady disease state for 3 months and no decrease in lung function exceeding 10% during that period
  • Colonization
  • Stable concomitant therapy >2 weeks prior to visit 1 and during the study
  • Non-tobacco user of any kind
  • Ability for sputum induction
  • Written informed consent

Exclusion Criteria:

  • Severe CF with an FEV1 of <25% predicted
  • History of lung transplant
  • Active allergic bronchopulmonary aspergillosis (ABPA)
  • Treatment with additional antibiotics (beyond standard CF treatment) for a period of 14 days before study entry (routine antibiotics permitted)
  • Treatment with additional oral and/or IV steroids (beyond standard CF treatment) for a period of 14 days before study entry (screening day)
  • Known hypersensitivity to plasma products
  • IgA deficiency
  • Uncontrolled hypertension
  • Lung surgery in the previous two years
  • Being on any thoracic surgery waiting list
  • Severe concomitant disease
  • Hospitalization within 1 month before study entry, not due to an airway disease
  • Severe liver cirrhosis with ascites
  • Hypersplenism
  • Grade III/IV oesophageal varices
  • Active pulmonary exacerbation within the 4 weeks prior to screening
  • History of significant hemoptysis within the previous year
  • Use of tobacco products or recreational drugs
  • Pregnancy or breastfeeding
  • Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with patient treatment, assessment, or compliance with the protocol.
  • Being a female of child-bearing age without adequate contraception
  • Participation in research study within 1 month
5 Years and older
Contact information is only displayed when the study is recruiting subjects
Kamada-AAT (inhaled)-003
Not Provided
Kamada, Ltd.
Not Provided
Principal Investigator: Eitan Kerem, MD Hadassah Hebrew University, Medical Center, Mt. Scopus, Jerusalem
Kamada, Ltd.
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP